About
Metcela is a clinical-stage biotechnology company focused on developing regenerative cell therapies for chronic diseases, particularly cardiovascular conditions like heart failure. Their lead asset, MTC001, utilizes autologous cardiac fibroblasts to repair damaged heart tissue, with a proprietary delivery system for precise administration. They also acquired Japan Regenerative Medicine Co., Ltd., which develops cardiac stem cell-based therapy for pediatric congenital heart diseases.
Tags
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Metcela do?
Metcela is a clinical-stage biotechnology company focused on developing regenerative cell therapies for chronic diseases, particularly cardiovascular conditions like heart failure. Their lead asset, MTC001, utilizes autologous cardiac fibroblasts to repair damaged heart tissue, with a proprietary delivery system for precise administration. They also acquired Japan Regenerative Medicine Co., Ltd., which develops cardiac stem cell-based therapy for pediatric congenital heart diseases.
How much funding has Metcela raised?
Metcela has raised a total of $37M in funding. The most recent round on record is Series C.
Where is Metcela headquartered?
Metcela is headquartered in Tokyo, Japan.
When was Metcela founded?
Metcela was founded in 2012.